IMPORTANCE Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by loss of upper and lower motor neurons. Although novel ALS genetic variants have been identified, the shared genetic risk between ALS and other neurodegenerative disorders remains poorly understood.
A myotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are thought to represent a continuous disease spectrum. 1 Clinically, ALS presents as progressive muscle wasting, hyperreflexia, and spasticity, whereas FTD is defined by cognitive and behavioral dysfunction. Between 40% and 50% of patients with ALS present with FTDassociated clinical phenotypes, including progressive aphasia, language impairment, and executive dysfunction. 1 Neuropathologically, ALS is defined by the loss of upper and lower motor neurons and the formation of TDP-43, SOD1, and ubiquitin-positive inclusions within motor neurons. Frontotemporal dementia is defined by atrophy of the frontal and temporal lobes, and subtypes of FTD are distinguished by the types of inclusions in these regions (tau, FUS, TDP-43, and ubiquitin). 2 Comparatively less is known about the shared pathobiology between ALS and other neurodegenerative diseases, such as Alzheimer disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Parkinson disease (PD). Genetic factors offer insights into the molecular mechanisms underlying disease. Rare mutations in TDP43 (GenBank 3435) are associated with ALS and FTD. [3] [4] [5] Genetic studies have revealed expansions of the hexanucleotide repeat within the noncoding promoter region of C9orf72 (GenBank 203228) as the cause of ALS and FTD. 6, 7 However, beyond
C9orf72 and TDP43, the genetic overlap across sporadic forms of ALS, FTD, and other neurodegenerative diseases remains poorly understood. One approach to assessing additional genetic risk among these diseases is to identify single-nucleotide polymorphisms (SNPs) that are jointly associated with multiple traits. [8] [9] [10] [11] Using previously validated methods, we investigated the genetic overlap between ALS, FTD, PSP, CBD, AD, and PD. We then used molecular and bioinformatics approaches to begin to define the role that these shared risk genes play in neurodegeneration.
Methods

Participant Samples
We evaluated summary statistics (P values and odds ratios) from genome-wide association studies (GWASs) for ALS, PD, AD, CBD, PSP, sporadic FTD, and autosomal dominant FTD with TDP-43 inclusions (eTable 1 in the Supplement). The GWASs were performed for individuals of European descent. Samples have been previously described in detail. [12] [13] [14] [15] [16] [17] [18] The data set on ALS represents 31 independent cohorts of participants with ALS and control participants. 14 Amyotrophic lateral sclerosis was diagnosed as probable or definite according to the 1994 El Escorial Criteria by neurologists specializing in motor neuron diseases. 19 The data set on sporadic FTD included multiple subtypes within the FTD spectrum: behavioral variant FTD, semantic dementia, progressive nonfluent aphasia, and FTD overlapping with motor neuron disease. The relevant institutional review boards or ethics committees approved the research protocol of the individual GWASs used in the present analysis, and all human participants gave written informed consent. The Human Research Protection Program Institutional Review Board at University of California San Francisco waived consent for all participants. The Institutional Review Board determined that the use or disclosure of the information does not adversely affect the rights and welfare of the individuals and involves no more than a minimal risk to their privacy.
Statistical Analysis Genetic Enrichment
We applied previously validated statistical methods to assess shared genetic risk and identify ALS susceptibility loci. 9, 10, [20] [21] [22] We evaluated SNPs associated with increased risk for ALS and FTD, ALS and PD, ALS and AD, ALS and CBD, ALS and PSP, and ALS and FTD with TDP-43 inclusions. Using this approach, the genetic enrichment of phenotype A with phenotype B exists if the proportion of SNPs or genes associated with phenotype A increases as a function of the increased association with phenotype B. To evaluate enrichment, we constructed foldenrichment and quantile-quantile plots of nominal -log 10 P values for all ALS SNPs and for subsets of SNPs determined by the significance of their association with PD, AD, CBD, PSP, and FTD (sporadic FTD and FTD with TDP-43 inclusions) (eFigure 1 in the Supplement). Enrichment can be directly interpreted in terms of the true discovery rate, which is equal to 1 minus the false discovery rate (FDR) (eAppendix 1 in the Supplement). 9, 10, [20] [21] [22] To minimize false positives, we used a 100-iteration random pruning with a linkage disequilibrium (LD) r 2 <0.2.
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conjunction FDR to illustrate the genomic location of the shared genetic risk loci.
Identification of Novel Risk Loci-Conditional FDR
To identify specific ALS susceptibility loci as a function of genetic variants associated with the 6 neurodegenerative disorders, we computed conditional FDRs. 20, 21 The conditional FDR is an extension of the standard FDR, which incorporates information from GWAS summary statistics of a second phenotype to adjust its significance level. The conditional FDR is defined as the probability that an SNP is null in the first phenotype given that the P values in the first and second phenotypes are as small as or smaller than the observed ones. Ranking SNPs by the standard FDR or by P values gives the same ordering of SNPs. In contrast, if the primary and secondary phenotypes are related genetically, the conditional FDR reorders SNPs and results in a different ranking than that based on P values alone. We used an overall FDR threshold of P < .05 to indicate statistical significance, which means 5 expected false discoveries per 100 reported. In addition, we constructed Manhattan plots based on the ranking of the conditional FDR to illustrate the genomic location. In all analyses, we controlled for the effects of genomic inflation by using intergenic SNPs (eAppendix 1 in the Supplement). Detailed information on the conditional FDR can be found in prior reports.
20,21
Functional Evaluation of Shared Risk Loci To determine whether the conjunction and conditional SNPs shared across ALS, PD, AD, CBD, PSP, and FTD (sporadic FTD and FTD with TDP-43 inclusions) modify gene expression, we evaluated cis-expression quantitative trait loci (eQTL) in a publicly available data set from neuropathologically confirmed control brains (UK Brain Expression Consortium, http://braineac.org/).
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To minimize multiple comparisons, we analyzed eQTL for the mean P value derived across the following brain regions: the cerebellum, frontal cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, temporal cortex, thalamus, and white matter. To minimize false positives, we applied a Bonferronicorrected P value of 1.5 × 10 −3 . To test for association between genotypes and gene expression, we used an analysis of covariance. We tested SNPs using an additive model in SAS (SAS Institute Inc). To evaluate cis-acting splicing quantitative trait loci (sQTL), we examined the associations of our shared risk SNPs with alternative splicing in control human brains. 24 Each study reported genetic and expression data on brains from individuals of European descent.
Differential Expression of Shared Genetic Risk Variants in Tissues of Patients With ALS, PSP, FTD, AD, or PD To determine whether shared risk genes identified by the conjunction FDR, the conditional FDR, and genes in cis-eQTL were differentially expressed in tissue from patients with ALS compared with controls, we analyzed the gene expression of the target genes in motor neurons isolated from 11 patients with ALS and controls (Gene Expression Omnibus [GEO] accession number GSE833). 25 To validate the genes identified in GSE833, we examined expression data from a well-characterized mouse model.
26
The RNA expression data were analyzed in nontransgenic SOD1 WT and SOD1 G93A mice at 75 and 110 days (GEO accession number GSE4390). 27 SOD1 G93A mice are presymptomatic at 75 days and exhibit hindlimb paralysis at 110 days. 26, 27 To determine whether differentially expressed genes in ALS were altered across brains with neurodegenerative disease, we analyzed the gene expression of the target genes using publicly available data sets. Differential gene expression was analyzed from the following data sets: the temporal cortices from patients with PSP and control brains (Synapse ID No. syn6090802) 28 and the frontal, hippocampus, and cerebellum from patients with FTD and controls (GEO accession number E13162 
Results
Selective Shared Genetic Risk Between ALS, PD, AD, CBD, PSP, and FTD
We identified enrichment in ALS SNPs across different levels of significance with FTD, PSP, and CBD ( Figure 1 ). Applying progressively stringent P value thresholds for ALS SNPs (ie, increasing values of nominal -log 10 P value), we found up to 300-fold enrichment using FTD with TDP-43 inclusions, 150-fold enrichment using FTD, 75-fold enrichment using PSP, and 25-fold enrichment using CBD ( Figure 1 ). In contrast, we found minimal or no enrichment in ALS SNPs as a function of AD or PD (Figure 1 ). At a conjunction FDR P < .05, we identified 5 SNPs that were jointly associated with increased risk for ALS and FTD with TDP-43 inclusions, ALS and FTD, or ALS and PSP ( Figure 1 and Table 1 ). These SNPs included the following: (1) A, Fold-enrichment plots. Graphs depict enrichment vs nominal −log 10 P values (corrected for inflation) in amyotrophic lateral sclerosis (ALS) below the standard genome-wide association study threshold of P <5×10 −8 as a function of significance of association with Parkinson disease (PD), Alzheimer disease (AD), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD) (sporadic and FTD with TDP-43 inclusions [TDP43] ) and at the level of −log 10 P Ն 0 corresponding to −log 10 P Յ 1, −log 10 P Ն 1 corresponding to P Յ .10, and -log 10 P Ն 2 corresponding to P Յ .01. B, Conjunction Manhattan plot showing shared risk loci. A plot of conjunction −log 10 (false discovery rate [FDR] ) values for ALS given PSP, CBD, TDP-43, and FTD. Single-nucleotide polymorphisms (SNPs) with conjunction −log 10 FDR > 1.3 (ie, FDR P < .05) are shown as large points. A black line around the large points indicates the most significant SNP in each linkage disequilibrium block. This SNP was annotated with the nearest gene, which is listed above the symbols in each locus. 
eQTL and sQTL
To begin to define the functional effects of these shared risk SNPs, we evaluated cis-eQTL in human brains free of neuropathologic characteristics ( Table 2 ). The SNP rs7224296 near NSF has been previously reported to tag the MAPT H1 haplotype. 9 The MAPT H1 haplotype is associated with increased risk for FTD, PSP, CBD, AD, and PD. 10, 11, 13, [16] [17] [18] However, the most significant cis-eQTL with 24296 occurred with KIAA1267 (GenBank 284058) (also known as KANSL1) ( Table 2 ). rs7224296 is in high LD with rs199533 (D′ = -0.97), which was previously reported to be associated with shared risk for PSP, CBD, and FTD. 9 Consistent with previous findings for rs199533, 9 rs7224296 is significantly associated with the altered expression of exon 3 within the MAPT gene (Table 2) . MAPT H1 is associated with decreased expression of messenger RNA transcripts containing exons 2 and 3, which results in the 2N tau protein. 32 Together, these findings point to an association between the MAPT H1 haplotype and the risk for ALS. We also identified 2 SNPs sharing genetic overlap between ALS and FTD or ALS and FTD with TDP-43 inclusions near C9orf72: rs13302855 and rs3849942 (Table 1) . These SNPs are not in LD (r 2 < 0.02). The SNP rs13302855 produced distinct eQTL with LRRC19 (GenBank 64922), and rs3849942 produced distinct eQTL with MOBKL2B (GenBank 79817) ( Table 2) . Thus, our findings suggest that there are 2 independent signals within the C9orf72 locus that confer risk. In addition to cis-eQTL, we examined the association of shared risk SNPs with sQTL. We found that rs2282241 (nearest gene, C9orf72; conditional FDR ALS and FTD with TDP-43 inclusions, P =3. 68×10 −5 ;ALSP =1.55×10 −7 ) was significantly associated with alternative splicing of the C9orf72 gene (alternative splicing ID, HsaINT0025532; FDR P =1. 08×10 −3 ), specifically intron retention. The sQTL SNP rs2282241 is in high LD with rs3849942 (D′ = 0.99; Table 1 ). Among the novel ALS risk SNPs identified by conditional FDR analysis, we identified cis-eQTL in human brains (eTable 3intheSupplement). Most ALS risk SNPs produced cis-eQTL with genes within the associated locus but not with the nearest named gene. We found that rs538622, which is associated with ALS and FTD and falls near the ERGIC1 gene, is significantly associated with BNIP1 (GenBank 662) such that the minor allele (G) is associated with the lower expression of BNIP1 in human brains (P =1.1×10 −3 ). 
Shared Genetic Risk Genes Reveal Dysregulation of Neuronal Networks
To determine whether the shared risk genes fall within common biological pathways, we used bioinformatics approaches to identify common pathways. Because most risk SNPs occur within intergenic regions, we used 2 approaches to associate a risk SNP with a gene: genes nearest the SNPs and genes producing eQTL with the SNPs. Pathway analysis reveals that shared risk genes, from conjunction and conditional analyses, fall within pathways directly involved in neuronal function: axon guidance, myelin sheath, synaptic vesicle pathways, neuronal action potential, and regulation of postsynaptic membrane potential, among others ( Table 3 ; eTables 4and5intheSupplement).
Differential Expression of Shared Risk Genes in Tissues of Patients With ALS, FTD, PSP, AD, or PD
We next sought to determine whether the risk genes shared across ALS, FTD, PSP, and CBD were differentially expressed in disease tissues. To make this determination, we assessed the differential expression of the genes nearest the top SNP from conditional and conjunction FDR analyses and of the genes that produced the strongest eQTL in our functional analyses in motor neurons isolated from spinal cords of patients with ALS and controls (genes included in the analysis were taken from Tables 1 and 2 and from eTables 2 and 3 in the Supplement). 25 Only 15 genes fitting these criteria were present in the ALS data set: BNIP1, C20orf24 (GenBank 55969), CAT (GenBank 847), CD59 (GenBank 966), ELL (GenBank 8178), GPX3 (GenBank 2878), HTRA2 (GenBank 27429), MOBP, MAPT, NFASC (GenBank 114), NSF, SCN5A (GenBank 6331), TEK (GenBank 7010), TNFAIP1 (GenBank 7126), and TNIP1 (GenBank 10318). We found that BNIP1 was significantly lower in motor neurons isolated from patients with ALS compared with controls ( Figure 2A ; eTable 6 in the Supplement). MAPT and MOBP were not differentially expressed in the motor neurons in patients with ALS and controls (eTable 6 in the Supplement).
Given the genetic overlap, we next examined BNIP1 expression in the brains of patients with FTD and PSP. Compared with controls, the BNIP1 expression was significantly reduced in the brains of patients with a neuropathologic diagnosis of FTD and PSP ( Figure 2B and C). MAPT expression was not significantly altered in the brains of patients with FTD or PSP relative to controls (eTable 6 in the Supplement).
To further assess whether BNIP1 expression is associated with ALS pathologic characteristics, we examined BNIP1 expression in the spinal cords from a transgenic mouse model of ALS.
26,27 BNIP1 expression was significantly reduced in the spinal cord of SOD1 G93A mice compared with SOD1 WT mice ( Figure 2G ). Thus, BNIP1 expression is associated with ALS pathologic characteristics. 
Discussion
Using summary statistics from large GWASs (124 876 individuals) and established genetic methods, we investigated the genetic overlap between ALS, FTD (sporadic FTD and FTD with TDP-43 inclusions), PD, AD, CBD, and PSP. At a conjunction FDR of P < .05, we identified up to 300-fold enrichment in genetic risk for ALS across different levels of significance for FTD and PSP. Conjunction FDR analyses revealed shared loci previously associated with ALS risk as well as several loci not previously implicated in disease risk but that point to genetic drivers of neuronal function and mitophagy. Using this approach, we report novel genetic overlap between ALS and diseases of the FTD spectrum within the MAPT H1 haplotype.
We observed multiple signals within chromosome 9 that were associated with risk between ALS and FTD (the cohort defined by TDP-43 pathologic characteristics) and ALS and PSP. Among these, rs3849942 is associated with C9orf72 repeat expansions that cause ALS and is used as a surrogate marker for the C9orf72 expansion haplotype. [34] [35] [36] Consistent with these reports, our sQTL findings suggest that SNPs in LD with rs3849942 modify C9orf72 splicing. Thus, it is likely that C9orf72 expansion carriers are present in multiple data sets and are driving some of the association. However, given that rs3849942 is not in LD with a second SNP near C9orf72, 302855, we may be detecting an independent signal on chromosome 9 that is associated with the risk for ALS, FTD, and PSP. Mutations in MAPT cause autosomal dominant forms of FTD.
37 Among FTD, PSP, and CBD, common variants in MAPT that tag the H1 haplotype represent the strongest genetic predictor of disease. 10, 11, 13, [16] [17] [18] In addition, the MAPT H1 haplotype has been associated with PD and AD. 10, 11, 13, [16] [17] [18] The MAPT H1 haplotype has recently been implicated in ALS risk in a metaanalysis of publications on neurodegenerative disease. 38 The risk SNP tagging the MAPT H1 haplotype, rs7224296, is associated with altered splicing of MAPT of exon 3, which, together with exon 2, encodes 2N-containing transcripts. Although the role that individual MAPT transcripts play in normal physiology and disease remains poorly understood, a recent study of human-induced pluripotent stem cell-derived neurons from MAPT haplotype carriers suggests that the H1 haplotype influences axonal transport velocities. 39 In ALS, these potential gene-induced deficits in axonal transport could alter disease onset and/or progression. Conditional FDR analyses offer the opportunity to begin to reveal novel ALS risk loci. Using this approach, we identified 29 SNPs at a conditional FDR of P < .05. Within chromosome 5, we identified a risk locus at rs538622 (nearest gene, ERGIC1) that produced a significant eQTL in human brains with BNIP1. BNIP1 is a proapoptotic protein (Bcl-2 family member) involved in the regulation of endoplasmic reticulum structure and mitophagy.
40,41 BNIP1 is highly expressed in neurons (eFigure 3intheSupplement). More important, we demonstrate that BNIP1 is significantly lower in central nervous system tissues from patients with ALS, FTD, and PSP. Because neuronal cell loss is a hallmark feature of neurodegenerative disease and because BNIP1 is a neuronally expressed gene, we find that BNIP1 is specifically reduced in both motor neurons isolated from the spinal cords of patients with ALS compared with the motor neu- Functionally, beyond mitophagy, we observed enrichment in shared risk genes occurring in pathways involved in neuronal health and maintenance. This finding, taken together with the relative lack of enrichment of genes in ALS, AD, and PD, points to the important role that genes involved in neuronal heath and function play in driving ALS, FTD, and PSP. Together, this study provides genetic, molecular, and functional insights into the effects of risk variants shared across the ALS-FTD spectrum.
Limitations
Beyond BNIP1, by leveraging statistical power from large neurodegenerative GWASs, we identified numerous novel ALS genetic variants. Although these SNPs warrant replication in an independent cohort, our findings suggest that sporadic ALS may represent a polygenic disorder characterized by numerous genetic variants, each of which has a small association with disease risk. Although no single common variant may be informative clinically, the additive combination of risk variants may help identify individuals who are at greatest genetic risk for ALS. The GWASs used in these analyses were performed for participants of European decent; thus, our findings of the genetic architecture of ALS and FTD spectrum disorders may be biased for individuals of European decent. Future studies conducted in large nonEuropean populations will be critical for gaining a more complete understanding of the genetic architecture underlying ALS and FTD spectrum disorders.
Conclusions
By integrating GWAS data with gene expression data from neurodegenerative disease and transgenic mouse models, our multimodal findings implicate the MAPT H1 haplotype in ALS and BNIP1 in the ALS-FTD spectrum. Additional work will be required to understand the role that tau plays in ALS and the relationship between BNIP1, mitophagy, and neurodegenerative diseases. interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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